UbiVac CEO to address World Life Science Conference in Beijing
Date: November 2, 2016
UbiVac CEO to address World Life Science Conference in Beijing
Beijing, China.-- UbiVac, www.ubivac.com, a private, clinical-stage immuno-oncology company with a lead product that educates the immune system to recognize and destroy cancer, announced that its co-founder and CEO, Bernard A. Fox, PhD, will address the World Life Science Conference in Beijing and co-chair a session on November 2nd entitled Clinical Medicine: Immunotherapy and Biotherapy. Professor Zhigang Tian, president of the Chinese Society for Immunology, will co-chair the session.
Conference speakers include 13 Nobel Laureates and 400 top professors from around the world. Dr. Fox will provide his perspective on immunoscore/ Immunoprofiling and combination immunotherapy including vaccines. His remarks will include insights gained during more than 30 years of research in cancer immunotherapy including his participation in the Society for Immunotherapy leading to the global Immunoscore project. He also will discuss how UbiVac’s DRibble immunotherapy (DPV-001) might be used to induce immunity in the majority of patients with cancer who lack apparent anticancer immunity.
DPV-001 is a first in class technology that combines more than 100 cancer targets, DAMPs and TLR agonist activity in a DC-targeted microvesicle. Phase II clinical trials have confirmed that DRibble technology is novel and can help induce immunity against cancer.
UbiVac believes that DRibble technology is the ideal companion for combination immunotherapy, and is complimentary to the pipelines of major pharmaceutical companies currently developing immuno-oncology therapies. DPV-001 currently is being evaluated in an NCI-supported, randomized, multi-center Phase II clinical trial.
In addition, UbiVac’s technology already is in a clinical trial for men with prostate cancer and will soon open a trial for patients with breast cancer.
“We are pleased to participate in this important conference and to be part of advancing the task of finding a cure for cancer,” Dr. Fox said. Recently UbiVac expanded its laboratory and office facilities in Portland, Oregon with a second location that provides more than 15,000 square feet for manufacturing and staff additions necessary to make further advance the company’s technology.
Award Number R44CA121612 from the National Cancer Institute supports the ongoing research and clinical trial of DPV-001.
Contact: Patricia Pearson, [email protected],
UbiVac is a clinical stage Immuno-Ongology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A. Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.